Compare Sibanye Stillwater Ltd (SBSW) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sibanye Stillwater Ltd vs Tango Therapeutics Inc. — how do they compare? Sibanye Stillwater Ltd trades at $9.63 (market cap $6.99B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Sibanye Stillwater Ltd is the larger of the two by market cap, and Sibanye Stillwater Ltd pays a 8.17% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sibanye Stillwater Ltd for 51 Days and Tango Therapeutics Inc. for 0 Days on average.
| SBSW | TNGX | |
|---|---|---|
Market Cap | $6.99B | $3.75B |
Volume | 3,905,859 | 9,619,106 |
Sector | Basic Materials | Health |
52-Week High | $21.12 | $32.90 |
52-Week Low | $8.00 | $7.50 |
Typical Hold Time | 51 Days | 0 Days |
Enterprise Value | $7.89B | $2.77B |
Dividend Yield | 8.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SBSW trades at $9.42, down 4.75% on the day, amid a bearish technical signal. The company reported a net loss of $5.17 billion in 2025 despite revenue of $129.68 billion, though profitability is projected to improve significantly in 2026. Analyst consensus is a Moderate Buy with a $14.25 price target. Recent news highlights strong first-half 2026 results, including 54% revenue growth and a surge in operating cash flow, signaling a potential turnaround.
The outlook for SBSW hinges on executing its growth roadmap and capital discipline. Investment opportunities include attractive valuation multiples and projected earnings recovery, but risks persist from commodity price volatility, high debt levels, and operational challenges in South African mining. The stock offers value if management delivers on its 2027-2028 targets.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
